Winston Dunn is a Gastroenterology physician affiliated with The University of Kansas Health System. OpenAlex indexes 109 publications with 3,746 citations (h-index 24); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3901 Rainbow Blvd, Rm 4035
Wescoe Mailstop 1023
Kansas City, KS 66160
Telephone
507-284-2511Registry record last updated 28 May 2014.
Clinical trials
- The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral
Sponsor: University of Kansas Medical Center
- OPTIMIzing muScle Preservation in paTients wIth Cirrhosis
Sponsor: University of Kansas Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Madrigal PharmaceuticalsProgram year202536 payments$47,466openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202514 payments$27,765openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.7%Rifamycin Antibacterial11.8%Xifaxan100%Part D≥46 patientsOsmotic Laxative5.5%Lactulose69%Constulose31%Part D≥27 patients+ 10 more classes in this area
Cardiovascular
27.8%Aldosterone antagonist (MRA)8.5%Spironolactone100%Part D≥50 patientsLoop diuretic7.5%Furosemide100%Part D≥46 patients+ 4 more classes in this area
Cancer & immunology
19.7%Calcineurin inhibitor17.4%Tacrolimus81%Cyclosporine Modified12%Cyclosporine4%Envarsus Xr4%Part D<11 patientsPurine Antimetabolite2.4%Azathioprine100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2017–2021 per NIH RePORTER. The latest:
- Factors Responsible for Liver Recovery After Successful Treatment of Hepatitis C.
University of Kansas Medical Center
FY2021$199,800K23DK109294 - Factors Responsible for Liver Recovery After Successful Treatment of Hepatitis C.
University of Kansas Medical Center
FY2020$199,800K23DK109294 - Factors Responsible for Liver Recovery After Successful Treatment of Hepatitis C.
University of Kansas Medical Center
FY2019$199,800K23DK109294
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
Alimentary Pharmacology & Therapeutics
2025 - ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease
The American Journal of Gastroenterology
2025 - Artificial Intelligence for Predictive Diagnostics, Prognosis, and Decision Support in MASLD, Hepatocellular Carcinoma, and Digital Pathology
Journal of Clinical and Experimental Hepatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Marilyn Rymer, MD
The University of Kansas Health System
Ryan Taylor, MD
The University of Kansas Health System
Clinton Humphrey, MD
The University of Kansas Health System
Gary Beauchamp, MD
The University of Kansas Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”